references
Project Portfolio
OVER 30 R&D PROJECTS and 15 NEW CHEMICAL ENTITIES in the pipeline
Research
Screen Hit to Lead Lead Opt. Pre-clinical
Translation
Phase I Phase IIa/PoC
SCYX1330682 SCYX1608210 oxaboroles
Development
Phase IIb/III Registration
Implementation
Access
Human African Trypanosomiasis (HAT) Leishmaniasis
SCYX-7158
Fexinidazole
NECT
Nifurtimox-Eflornithine Combination Therapy
Screening
Leish H2L
DNDI-5421 DNDI-5610 oxaboroles Amino pyrazoles CGH VL Series 1
DNDI-6148 oxaborole DNDI-0690 nitroimidazole
Fexi/MF combination
New Treatments for HIV/VL New Treatments for PKDL MF/Paromomycin combo for Africa New VL Treatments Latin America
SSG&PM
Africa
New VL Treatments
Asia
CpG-D35 (CL)
Anfoleish (CL)
New CL combination
Chagas
Screening
Chagas H2L
Chagas Lead Opt
New Benz Regimens +/fosravuconazole Fexinidazole
Benznidazole
Paediatric dosage form
Biomarkers
Filaria Paediatric HIV
Screening
Macro Filaricide 3
AbbV4083 TylAMac
Emodepside
Two ‘4-in-1’ LPV/r FDC granules
LPV/r pellets with dual NRTI
Superbooster Therapy
Paediatric HIV/TB
Hepatitis C Mycetoma
Ravidasvir/ Sofosbuvir Fosravuconazole
Malaria ASAQ FDC ASMQ FDC
New Chemical Entity (NCE); Fexinidazole (for HAT, VL, and Chagas) = 1 NCE; Fosravuconazole (for Chagas and mycetoma) = 1 NCE This portfolio was approved by the Board of DNDi in June 2016.
• R&D Portfolio
7
